AstraZeneca H376/95
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Company expects to file an NDA for the oral direct thrombin inhibitor in the second half of 2002 for prevention of venous thromboembolism in orthopedic surgery. The NDA filing was originally planned for 2001 but Phase III trials of the product did not achieve statistical superiority over comparator products enoxaparin and warfarin, according to the company. A submisison for prevention of stroke in atrial fibrillation is expected in the second quarter of 200
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.